Piramal Pharma

What does Piramal Pharma do?

Piramal Pharma Ltd is a large-cap company in the Pharmaceuticals & Biotechnology industry, offering a range of products and services with recent net sales of ₹2,754 Cr and a net profit of ₹154 Cr as of March 2025. The company has a market cap of ₹27,515 Cr and a P/E ratio of 304.00.

Overview:<BR>Piramal Pharma Ltd is a large-cap company operating in the Pharmaceuticals & Biotechnology industry, offering a portfolio of differentiated products and services through comprehensive manufacturing capabilities.<BR><BR>History:<BR>Piramal Pharma Ltd was incorporated on March 4, 2020, as a Public Limited Company. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 2,754 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 154 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 27,515 Cr (Large Cap)<BR><BR>Key Metrics:<BR>P/E: 304.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 0.05% <BR>Debt-Equity: 0.53 <BR>Return on Equity: 1.12% <BR>Price to Book: 3.40 <BR><BR>Contact Details:<BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

Who are in the management team of Piramal Pharma?

As of March 2022, the management team of Piramal Pharma includes Nandini Piramal (Chairperson), Peter D DeYoung (CEO), Vivek Valsaraj (CFO), and several independent directors, overseeing the company's strategic direction and operations.

As of March 2022, the management team of Piramal Pharma includes the following key individuals:<BR><BR>1. Nandini Piramal - Chairperson<BR>2. Peter D DeYoung - Executive Director & CEO<BR>3. Neeraj Bharadwaj - Director<BR>4. Jairaj Purandare - Independent Director<BR>5. S Rama Dorai - Independent Director<BR>6. Peter Stevenson - Independent Director<BR>7. Sridhar Gorthi - Independent Director<BR>8. Vibha Paul Rishi - Independent Director<BR>9. Nathalie Leitch - Director<BR>10. Vivek Valsaraj - Executive Director & CFO<BR>11. Tanya D'Costa - Company Secretary & Compliance Officer<BR><BR>This team is responsible for the strategic direction and operations of the company.

When is the next results date for Piramal Pharma?

No Upcoming Board Meetings

Has Piramal Pharma declared dividend?

Piramal Pharma Ltd has declared a 1% dividend, amounting to ₹0.1 per share, with an ex-date of July 12, 2024. The dividend yield is 0.05%, and while the company has shown strong returns over the past year and two years, recent performance has been negative in the last six months.

Piramal Pharma Ltd has declared a 1% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 1%<BR>- Amount per share: 0.1<BR>- Ex-date: Jul-12-2024<BR><BR>Dividend Yield: 0.05%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -22.43%, the dividend return was 0%, resulting in a total return of -22.43%.<BR><BR>Over the past year, the price return was 39.89%, the dividend return was 0.06%, leading to a total return of 39.95%.<BR><BR>In the 2-year period, the price return was 143.03%, the dividend return was 0.11%, which resulted in a total return of 143.14%.<BR><BR>For the 3-year period, both the price return and dividend return were 0%, resulting in a total return of 0.0%.<BR><BR>In the 4-year period, there was no price return or dividend return, leading to a total return of 0.0%.<BR><BR>Over the last 5 years, the price return and dividend return remained at 0%, resulting in a total return of 0.0%.<BR><BR>Overall, while Piramal Pharma has declared a dividend, the returns over the past periods show significant variability, particularly with strong returns in the 1 and 2-year periods compared to negative returns in the recent 6-month period. The dividend yield is relatively low, indicating that while there is a dividend, it may not be a primary attraction for investors.

Who are the peers of the Piramal Pharma?

Piramal Pharma's peers include Cohance Life, Ipca Labs, Ajanta Pharma, Gland Pharma, Wockhardt, J B Chemicals, Emcure Pharma, Pfizer, and ERIS Lifescience. In terms of management risk, growth, and capital structure, Piramal Pharma shows average performance, with a 1-year return of 40.51%, lower than Wockhardt's 116.70% but higher than J B Chemicals' -7.94%.

Peers: The peers of Piramal Pharma are Cohance Life, Ipca Labs, Ajanta Pharma, Gland Pharma, Wockhardt, J B Chemicals &, Emcure Pharma, Pfizer, and ERIS Lifescience.<BR><BR>Quality Snapshot: Excellent management risk is observed at Cohance Life and Ajanta Pharma, while Good management risk is found at Ipca Labs, Gland Pharma, J B Chemicals &, Emcure Pharma, and Pfizer. Average management risk is present at Wockhardt and Piramal Pharma. Below Average management risk is noted at none of the peers. In terms of Growth, Excellent growth is seen at Piramal Pharma, while Good growth is observed at Wockhardt, Average growth is found at Ipca Labs, J B Chemicals &, and the rest, while Below Average growth is noted at Cohance Life, Ajanta Pharma, Gland Pharma, Emcure Pharma, Pfizer, and ERIS Lifescience. For Capital Structure, Excellent capital structure is present at Cohance Life, Ipca Labs, Ajanta Pharma, Gland Pharma, J B Chemicals &, and Pfizer, while Good capital structure is noted at Emcure Pharma, and Below Average capital structure is observed at Wockhardt and Piramal Pharma.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Wockhardt at 116.70%, while the peer with the lowest is J B Chemicals & at -7.94%. Piramal Pharma's 1-year return of 40.51% is significantly higher than J B Chemicals & but lower than Wockhardt. Additionally, the peers with negative six-month returns include Piramal Pharma, J B Chemicals &, and Emcure Pharma.

Who are the top shareholders of the Piramal Pharma?

The top shareholders of Piramal Pharma include the Sri Krishna Trust with 26.62%, foreign institutional investors holding 31.49%, and mutual funds with 12.73%. The highest public shareholder is Ca Alchemy Investments at 18%, while individual investors own 13.11%.

The top shareholders of Piramal Pharma include the promoters, who hold the majority of the shares. Specifically, the Sri Krishna Trust, represented by Mr. Ajay G. Piramal and Dr. (Mrs.) Swati A. Piramal, has the highest holding at 26.62%. <BR><BR>In addition to the promoters, foreign institutional investors (FIIs) hold a significant stake of 31.49%, while mutual funds are represented by 25 schemes, accounting for 12.73% of the shares. The highest public shareholder is Ca Alchemy Investments, which holds 18%. Individual investors collectively own 13.11% of the company.

How big is Piramal Pharma?

As of 24th July, Piramal Pharma Ltd has a market capitalization of 27,316.00 Cr, with recent net sales of 9,151.18 Cr and a net profit of 91.13 Cr. The company's shareholder's funds are 8,125.47 Cr, and total assets amount to 15,284.46 Cr.

As of 24th July, Piramal Pharma Ltd has a market capitalization of 27,316.00 Cr, categorizing it as a Large Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 9,151.18 Cr and a Net Profit of 91.13 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 8,125.47 Cr and Total Assets of 15,284.46 Cr.

Is Piramal Pharma overvalued or undervalued?

As of November 27, 2025, Piramal Pharma is fairly valued with a PE ratio of -557.34, an EV to EBITDA of 24.82, and a Price to Book Value of 3.07, contrasting with peers like Sun Pharma and Cipla, while experiencing a year-to-date stock decline of 29.83% compared to the Sensex's gain of 9.70%.

As of 27 November 2025, Piramal Pharma's valuation grade has moved from expensive to fair. The company appears to be fairly valued at this time. Key ratios include a PE ratio of -557.34, an EV to EBITDA of 24.82, and a Price to Book Value of 3.07. <BR><BR>In comparison to its peers, Piramal Pharma's valuation stands out against Sun Pharma, which is considered expensive with a PE ratio of 37.62, and Cipla, which is rated attractive with a PE ratio of 22.67. Notably, Piramal's negative PE ratio indicates significant challenges, while its EV to EBITDA ratio is comparable to some peers but still reflects high leverage. Recent stock performance shows a decline of 29.83% year-to-date, contrasting sharply with the Sensex's gain of 9.70%, further emphasizing the company's current valuation context.

How has been the historical performance of Piramal Pharma?

Piramal Pharma has shown a generally upward trend in net sales and operating profit from Mar'22 to Mar'25, despite fluctuations in profit before and after tax. Total liabilities and assets have increased, indicating growth, while cash flow has been variable.

Answer:<BR>The historical performance of Piramal Pharma shows a fluctuating yet generally upward trend in key financial metrics over the past few years.<BR><BR>Breakdown:<BR>Piramal Pharma's net sales have increased from 6,559.10 Cr in Mar'22 to 9,151.18 Cr in Mar'25, reflecting a consistent growth in total operating income, which mirrors the sales figures. The total expenditure has also risen, reaching 7,706.35 Cr in Mar'25, up from 5,609.44 Cr in Mar'22. Operating profit (PBDIT) has shown improvement, climbing from 1,225.46 Cr in Mar'22 to 1,579.64 Cr in Mar'25, with the operating profit margin increasing to 15.79% in Mar'25 from 14.48% in Mar'22. Despite this, profit before tax has been volatile, with a notable drop to -174.48 Cr in Mar'23 before recovering to 341.71 Cr in Mar'25. Profit after tax has also fluctuated, moving from a high of 316.93 Cr in Mar'22 to a loss of 240.79 Cr in Mar'23, and then to a modest profit of 18.20 Cr in Mar'25. The consolidated net profit reflects this trend, showing a recovery from -186.46 Cr in Mar'23 to 91.13 Cr in Mar'25. On the balance sheet, total liabilities increased from 12,499.77 Cr in Mar'22 to 15,284.46 Cr in Mar'25, while total assets rose correspondingly, indicating a growing scale of operations. Cash flow from operating activities has been variable, peaking at 1,004.00 Cr in Mar'24 before dropping to 892.00 Cr in Mar'25, with net cash outflow recorded in Mar'25. Overall, Piramal Pharma's financial performance demonstrates resilience and growth potential despite some fluctuations in profitability.

Is Piramal Pharma technically bullish or bearish?

As of December 3, 2025, Piramal Pharma's technical trend has shifted to bearish, supported by negative indicators from MACD, moving averages, Bollinger Bands, and a lack of positive signals from RSI and OBV.

As of 3 December 2025, the technical trend for Piramal Pharma has changed from mildly bearish to bearish. The current stance is bearish with a strong indication from multiple indicators. The weekly MACD is bearish, and the daily moving averages also reflect a bearish trend. Bollinger Bands confirm bearish conditions on both weekly and monthly time frames. The Dow Theory indicates a mildly bearish stance on the weekly and monthly charts. Overall, the lack of positive signals from the RSI and OBV further supports the bearish outlook.

Are Piramal Pharma Ltd latest results good or bad?

Piramal Pharma Ltd's latest results are concerning, with a net loss of ₹136.19 crores for Q3 FY26, marking the third consecutive quarter of losses. Revenue declined year-on-year, and operating margins have significantly compressed, indicating serious profitability challenges and negative investor sentiment.

Piramal Pharma Ltd's latest results indicate a challenging financial situation. The company reported a consolidated net loss of ₹136.19 crores for Q3 FY26, which is a significant decline of 3,700.82% year-on-year. This marks the third consecutive quarter of losses, raising concerns about the sustainability of its business model.<BR><BR>Revenue for the quarter was ₹2,139.87 crores, showing a slight sequential growth of 4.70% from the previous quarter, but a decline of 2.92% compared to the same quarter last year. This ongoing revenue decline suggests weakening demand across its key business segments.<BR><BR>Operating margins have also compressed sharply, falling to 9.15% from 15.32% a year ago, reflecting significant cost pressures. The profit after tax (PAT) margin turned negative at -6.36%, compared to a marginal positive margin of 0.17% in the previous year.<BR><BR>Overall, the results are concerning, highlighting severe profitability challenges, margin erosion, and a lack of positive momentum in revenue growth. The stock has underperformed significantly, declining 33.60% over the past year, indicating deteriorating investor sentiment. Given these factors, the latest results can be characterized as bad for Piramal Pharma Ltd.

Should I buy, sell or hold Piramal Pharma Ltd?

Which are the latest news on Piramal Pharma?

Why is Piramal Pharma Ltd falling/rising?

As of 10-Apr, Piramal Pharma Ltd's stock price is rising to Rs 146.10, up 2.24%, but it has a poor long-term performance with a -29.86% return over the past year and significant debt concerns. Despite today's positive indicators, the company's ongoing challenges may impact future sustainability.

As of 10-Apr, Piramal Pharma Ltd's stock price is rising, currently at Rs 146.10, reflecting an increase of Rs 3.2 or 2.24%. This rise can be attributed to its performance today, where it outperformed its sector by 1.95% and reached an intraday high of Rs 147.1, which is a 2.94% increase. Additionally, the stock is trading above its 5-day and 20-day moving averages, indicating a short-term positive trend.<BR><BR>However, it is important to note that despite today's rise, the stock has faced significant challenges over a longer period. Over the past year, it has generated a return of -29.86%, which is a stark contrast to the market's performance, as the BSE500 has returned 9.24% in the same timeframe. The company has also reported negative results for the last three consecutive quarters, with a substantial decline in profit before tax and profit after tax compared to previous averages.<BR><BR>While the stock shows some positive indicators today, such as healthy long-term growth in operating profit and high institutional holdings at 45.35%, these are overshadowed by its poor overall performance and high debt levels. The company's high Debt to EBITDA ratio of 4.17 times raises concerns about its ability to service debt, which could impact future performance. Thus, while the stock is currently rising, the broader context suggests underlying weaknesses that could affect its sustainability.